NeuBase Therapeutics, Inc.
NBSEDelisted May 16, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173281
NeuBase Therapeutics, Inc. was delisted on May 16, 2024; its insiders filed their last Form 4 on Sep 18, 2023; 18 institutions reported holding it in 13F filings for Q1 2024, worth $177.1K in total; Greenlight Capital was the only superinvestor holding it.
Q3 2021 vs. Q2 2021
How the institutions holding NeuBase Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 59 | 48 | −11 |
| Shares | 10.8M | 10.1M | −625.8K (−5.8%) |
| Value | $51.5M | $36.6M | −$14.9M (−29.0%) |
New holders (1)
Institutions that held NeuBase Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| CM Management, LLC | 75,000 | $271.0K | 0.20% |
Sold out (12)
Institutions that held NeuBase Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Frontier Wealth Management LLC | 145,000 | $695.0K |
| Granite Point Capital Management, L.P. | 81,209 | $389.0K |
| First Trust Advisors LP | 73,098 | $350.0K |
| Tibra Equities Europe Ltd | 66,400 | $318.0K |
| Citadel Advisors LLC | 27,677 | $133.0K |
| Opal Wealth Advisors, LLC | 20,000 | $96.0K |
| Trexquant Investment LP | 19,230 | $92.0K |
| Walleye Capital LLC | 17,212 | $82.0K |
| Charles Schwab Investment Management Inc | 15,720 | $76.0K |
| Clean Yield Group | 3,100 | $15.0K |
| New York State Common Retirement Fund | 128 | $1.00K |
| Citigroup Inc | 1 | $0 |